Abstract
The fungal burdens (number of CFU per pair of lungs) in mice infected with Aspergillus fumigatus AB16.4 (for which the amphotericin B [AMB] MIC was elevated) and W73355 (drug-susceptible parent) were reduced by 21 and 81%, respectively, after 5 days of AMB treatment (2 mg/kg/day), indicating that AB16.4 also shows reduced susceptibility to AMB in a murine pulmonary aspergillosis model.
MeSH terms
-
Amphotericin B / pharmacology
-
Amphotericin B / therapeutic use*
-
Animals
-
Antifungal Agents / pharmacology
-
Antifungal Agents / therapeutic use*
-
Aspergillosis / drug therapy
-
Aspergillosis / microbiology
-
Aspergillus fumigatus / drug effects*
-
Aspergillus fumigatus / isolation & purification
-
Colony Count, Microbial
-
Disease Models, Animal
-
Drug Resistance, Bacterial*
-
Female
-
Humans
-
Laboratories
-
Lung / microbiology*
-
Lung Diseases, Fungal / drug therapy*
-
Lung Diseases, Fungal / microbiology
-
Mice
-
Mice, Inbred DBA
Substances
-
Antifungal Agents
-
Amphotericin B